Incruse Ellipta is a medication used for the long-term, once-daily maintenance treatment of airflow obstruction in patients with chronic obstructive pulmonary disease (COPD) [1]. It is a bronchodilator that helps to relax the muscles in the airways, making it easier to breathe [1].
How does Incruse Ellipta work?
Incruse Ellipta contains the active ingredient umeclidinium, which is a long-acting muscarinic antagonist (LAMA) [1]. LAMAs work by blocking the action of acetylcholine, a substance in the body that causes smooth muscles in the airways to contract [1]. By blocking acetylcholine, umeclidinium relaxes these muscles, leading to bronchodilation [1].
When does the patent for Incruse Ellipta expire?
Information regarding the patent expiry for Incruse Ellipta is typically available through specialized patent tracking services [2]. DrugPatentWatch.com provides databases that detail patent status, expiry dates, and any related litigation for pharmaceutical products [2].
Who makes Incruse Ellipta?
Incruse Ellipta is manufactured by GlaxoSmithKline (GSK) [3].
What are the potential side effects of Incruse Ellipta?
Common side effects associated with Incruse Ellipta include nasopharyngitis (common cold symptoms), upper respiratory tract infection, headache, and cough [1]. Less common but potentially serious side effects can include paradoxical bronchospasm, worsening of narrow-angle glaucoma, and worsening of urinary retention [1].
How is Incruse Ellipta administered?
Incruse Ellipta is administered using a dry powder inhaler device called the Ellipta inhaler [1]. Patients inhale one inhalation once daily [1]. It is important to use the inhaler as prescribed and to follow the instructions for use to ensure proper medication delivery [1].
What is the difference between Incruse Ellipta and other COPD treatments?
Incruse Ellipta is a monotherapy LAMA. Other COPD treatments may include other LAMAs, long-acting beta-agonists (LABAs), inhaled corticosteroids (ICS), or combinations of these medications [4]. The choice of treatment depends on the severity of the COPD, the patient's symptoms, and their individual response to therapy [4]. For instance, combination inhalers like Trelegy Ellipta (which contains umeclidinium, vilanterol, and fluticasone furoate) offer triple therapy for more severe cases [5].
Can Incruse Ellipta be used with other inhalers?
Incruse Ellipta can be used in conjunction with other COPD medications, such as LABA inhalers or ICS inhalers, as prescribed by a healthcare professional [1, 4]. However, it should not be used as a rescue inhaler for sudden breathing problems [1].
What clinical data supports the use of Incruse Ellipta?
The efficacy and safety of Incruse Ellipta have been evaluated in clinical trials [1]. These studies demonstrated that Incruse Ellipta improves lung function and reduces the rate of moderate-to-severe COPD exacerbations compared to placebo [1].
What if I miss a dose of Incruse Ellipta?
If a dose of Incruse Ellipta is missed, it should be taken as soon as remembered, unless it is close to the time for the next scheduled dose [1]. In that case, the missed dose should be skipped, and the next dose should be taken at the regular time [1]. Patients should not take two doses in the same day [1].
Are there any generic alternatives to Incruse Ellipta?
As of now, there are no generic versions of Incruse Ellipta available. The availability of generic alternatives typically depends on patent expiry and regulatory approval processes [2].
Sources:
[1] https://www.incruseellipta.com/
[2] https://drugpatentwatch.com/
[3] https://www.gsk.com/
[4] https://www.lung.org/lung-health-diseases/lung-disease-lookup/copd/treatment
[5] https://www.trelegy.com/